Evidence map›Paper›PMID 36142819›Full record

ArticleInternational journal of molecular sciences2022

Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein.

Yu-Lei Chen, Jin-Jin Lin, Huan Ma, Ning Zhong, Xin-Xin Xie, Yunru Yang, Peiyi Zheng, Ling-Jing Zhang, Tengchuan Jin, Min-Jie Cao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Protein-Protein Binding Kinetics by Biolayer Interferometry.Advances in experimental medicine and biology · 2024
    Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yu-Lei ChenCollege of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, China.ORCID 0000-0003-2893-6540
Jin-Jin LinCollege of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, China.
Huan MaCAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science & Technology of China, Hefei 230007, China.
Ning ZhongCollege of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, China.
Xin-Xin XieCollege of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, China.
Yunru YangCAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science & Technology of China, Hefei 230007, China.
Peiyi ZhengCAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science & Technology of China, Hefei 230007, China.
Ling-Jing ZhangCollege of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, China.
Tengchuan JinCAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science & Technology of China, Hefei 230007, China.ORCID 0000-0002-1395-188X
Min-Jie CaoCollege of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, China.
Jimei University · CNUniversity of Science and Technology of China · CN

Funding

National Key R&D Program of China 2018YFD0901004National Natural Science Foundation of China 31772049, 31702372Natural Science Foundation of Fujian Province 2021J01838
6 · The paper itself

Abstract

The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is the major target for antibody therapeutics. Shark-derived variable domains of new antigen receptors (VNARs) are the smallest antibody fragments with flexible paratopes that can recognize protein motifs inaccessible to classical antibodies. This study reported four VNARs binders (JM-2, JM-5, JM-17, and JM-18) isolated from

Indexed as

COVID-19 Drug TreatmentSharksAngiotensin-Converting Enzyme 2AnimalsEpitopesHumansImmunoglobulin FragmentsPeptidyl-Dipeptidase AProtein BindingReceptors, VirusSARS-CoV-2Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2EpitopesImmunoglobulin FragmentsPeptidyl-Dipeptidase AReceptors, VirusSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2bi-paratopic VNARRBDSARS-CoV-2sharkvariantsVNAR

Identifiers

PMID36142819
PMCPMC9502636
OpenAlexW4296352694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.